Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMU86XT)

• Drug Name: YM-201636 Drug Info
• Synonyms: 371942-69-7; YM201636; YM 201636; 6-Amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-3-pyridinecarboxamide; 3-pyridinecarboxamide, 6-amino-N-[3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl]-; 6-amino-n-(3-(4-(4-morpholinyl)pyrido(3',2'-4,5)furo(3,2-d)pyrimidin-2-yl)phenyl)-3-pyridinecarboxamide; 6-amino-N-[3-[4-(4-morpholinyl)-2-pyrido[2,3]furo[2,4-b]pyrimidinyl]phenyl]-3-pyridinecarboxamide; PubChem22459; cc-386; MLS006010997; SCHEMBL258416; CHEMBL2178735; CHEBI:91382; AOB1919; DTXSID90433303; EX-A037; QCR-257; BCPP000006; HMS3229J15; HMS3295C07; HMS3654F03; AMY23718; BCP01972; ABP000099; MFCD16038303; s1219; ZINC34048998; AKOS027250783; CCG-264866; CS-0592; NCGC00346683-01; NCGC00346683-09; 6-amino-N-[3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)phenyl]pyridine-3-carboxamide; AK175782; AS-16693; HY-13228; SMR004702795; AB0035851; FT-0756177; SW218129-2; Y0272; A19418; W-5608; 942Y697; J-518249; BRD-K48488978-001-01-2; Q27163245; YM-201636,CAS:371942-69-7; 6-Amino-N-[3-(6-morpholin-4-yl-8-oxa-3,5,10-triazatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaen-4-yl)phenyl]pyridine-3-carboxamide; 6-Amino-N-{3-[4-(morpholin-4-yl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenyl}pyridine-3-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Preclinical	[1]

• Cross-matching ID:
  PubChem CID: 9956222
  ChEBI ID: CHEBI:91382
  CAS Number: CAS 371942-69-7
  TTD Drug ID: DMU86XT

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apilimod dimesylate	DM4N2O0	Non-hodgkin lymphoma	2B33.5	Phase 2	[3]
LAM-002	DMR0N74	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3)	TTA4M1N	FYV1_HUMAN	Inhibitor	[2]

References

• [1] Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948.
• [2] PIKfyve negatively regulates exocytosis in neurosecretory cells. J Biol Chem. 2008 Feb 1;283(5):2804-13.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)